Efficacy and Safety of Novel‐Agent–Based Front‐Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta‐Analysis
- 22 June 2026
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 44 (4) , e70215
Abstract
Older patients with classical Hodgkin lymphoma (cHL) have poorer outcomes than younger patients, largely due to comorbidities, reduced chemotherapy tolerance, and limited representation in clinical trials. Brentuximab Vedotin (BV) and PD‐1 inhibitors have entered frontline use in this population, but the optimal approach remains uncertain. We performed a systematic review and pooled analysis to evaluate the efficacy and safety of frontline regimens in patients aged ≥ 60 years with cHL. Studies reporting complete response (CR), overall response rate (ORR), progression‐free survival (PFS), and toxicity were included. Outcomes were pooled using random‐effects models. A total of 11 studies including 568 patients were analyzed. The pooled CR rate was 71% (95% CI: 57–81) and pooled 2‐year PFS was 66% (95% CI: 45–83), with significant heterogeneity. Nivolumab‐based regimens appeared, in indirect subgroup comparisons with marked heterogeneity, to have a higher pooled response rates and PFS than BV‐based regimens, and were associated with lower rates of treatment discontinuation, Grade ≥ 3 infections, and neuropathy. Novel agent‐based regimens produced better efficacy and lower toxicity than traditional chemotherapy in newly diagnosed older adults with cHL. Among novel agents, nivolumab‐based regimens had more favorable efficacy and tolerability than BV‐based regimens, though these comparisons are indirect and may reflect differences in study design and patient selection.Keywords
This publication has 12 references indexed in Scilit:
- A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trialBritish Journal of Haematology, 2025
- Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term resultsBlood Advances, 2025
- Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyBlood, 2024
- Hodgkin lymphoma treatment for older persons in the modern eraHematology-American Society Hematology Education Program, 2023
- Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry StudyClinical Lymphoma Myeloma and Leukemia, 2023
- Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s LymphomaNew England Journal of Medicine, 2022
- Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyHaematologica, 2021
- Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)British Journal of Haematology, 2020
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 StudyJournal of Clinical Oncology, 2019
- Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin LymphomaJournal of Clinical Oncology, 2018